LITFULO▼ (ritlesitinib): Direct Contact for Healthcare Professionals

Litfulo▼ (ritlesitinib): Updated recommendations to minimize the risk of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality.

For the full text of the announcement click here.